BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19262252)

  • 1. 8q deletion in MYCN-amplified neuroblastoma of a child born from assisted reproductive technology.
    Brassesco MS; Valera ET; de Oliveira FM; de Paula Queiroz RG; Scrideli CA; Sakamoto-Hojo ET; Tone LG
    J Pediatr Hematol Oncol; 2009 Mar; 31(3):215-9. PubMed ID: 19262252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
    Passariello A; De Brasi D; Defferrari R; Genesio R; Tufano M; Mazzocco K; Capasso M; Migliorati R; Martinsson T; Siani P; Nitsch L; Tonini GP
    Eur J Med Genet; 2013 Nov; 56(11):626-34. PubMed ID: 24035971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A MYCN-amplified cell line derived from a long-term event-free survivor among our sixteen established neuroblastoma cell lines.
    Sugimoto T; Gotoh T; Yagyu S; Kuroda H; Iehara T; Hosoi H; Ohta S; Ohira M; Nakagawara A
    Cancer Lett; 2013 Apr; 331(1):115-21. PubMed ID: 23268333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of modified Shimada classification with MYCN and 1p36 status detected by fluorescence in situ hybridization in neuroblastoma.
    Altungoz O; Aygun N; Tumer S; Ozer E; Olgun N; Sakizli M
    Cancer Genet Cytogenet; 2007 Jan; 172(2):113-9. PubMed ID: 17213019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.
    Berbegall AP; Villamón E; Piqueras M; Tadeo I; Djos A; Ambros PF; Martinsson T; Ambros IM; Cañete A; Castel V; Navarro S; Noguera R
    Oncogene; 2016 Mar; 35(11):1423-32. PubMed ID: 26119945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
    Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
    Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
    Wan TS; Ma ES; Chan GC; Chan LC
    Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of single-copy chromosome 17q gain in human neuroblastomas using real-time quantitative polymerase chain reaction.
    Morowitz M; Shusterman S; Mosse Y; Hii G; Winter CL; Khazi D; Wang Q; King R; Maris JM
    Mod Pathol; 2003 Dec; 16(12):1248-56. PubMed ID: 14681326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.
    Tumer S; Altungoz O; Bagci O; Olgun HN
    Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.
    Villamón E; Piqueras M; Mackintosh C; Alonso J; de Alava E; Navarro S; Noguera R
    Virchows Arch; 2008 Jul; 453(1):47-55. PubMed ID: 18574593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of karyotypic events and evolution in neuroblastoma.
    Betts DR; Cohen N; Leibundgut KE; Kühne T; Caflisch U; Greiner J; Traktenbrot L; Niggli FK
    Pediatr Blood Cancer; 2005 Feb; 44(2):147-57. PubMed ID: 15390360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
    Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
    Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
    Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
    Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetic tumor background is an important determinant for heterogeneous MYCN-amplified neuroblastoma.
    Bogen D; Brunner C; Walder D; Ziegler A; Abbasi R; Ladenstein RL; Noguera R; Martinsson T; Amann G; Schilling FH; Ussowicz M; Benesch M; Ambros PF; Ambros IM
    Int J Cancer; 2016 Jul; 139(1):153-63. PubMed ID: 26910568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
    Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
    Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.